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Background: Human papillomavirus (HPV) infection is associated with cervical cancer, the most frequent cancer in
women from northern Brazil. Assessment of the short-term impact of HPV vaccination depends on the availability
of data on the prevalence of type-specific HPV in young women in the pre-immunization period, although these data
are currently unavailable for the study region. The aim of this study was to estimate the distribution of all mucosal HPV
genotypes, including low- and high-risk HPV types, in unvaccinated college students from northern Brazil.
Findings: Specimens were collected from 265 university students during routine cervical cancer screening. The HPV
DNA was assessed by Polymerase Chain Reaction and positive samples were genotyped by Restriction Fragment
Length Polymorphism. Most students (85.7 %) had normal cytological results. The prevalence of HPV was 25.3 %
(67/265), with a high frequency of multiple infections and non-vaccine high-risk HPV genotypes. The most prevalent
type was HPV-61 (5.3 %), followed by types 82, 16, 59, and 6. Multiple infections were associated with high-risk and
possibly high-risk HPVs.
Conclusions: We demonstrated a high prevalence of HPV infection in university students from northern Brazil. Vaccine
high-risk types were relatively rare, emphasizing the predominance of carcinogenic genotypes that are not prevented
by the currently available vaccines. Our study highlights the need to reinforce cytological screening in women from
northern Brazil, and promote the early diagnosis and treatment of the precancerous lesions associated with cervical
cancer.
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Introduction
Human papillomavirus (HPV) is a non-enveloped double-
stranded DNA virus of the family Papillomaviridae [1].
Persistent infections with high-risk HPVs (hrHPV) can
progress to Cervical Cancer (CC) [2]. While this cancer is
the third most common in women both worldwide [3],
and in Brazil in general, it is the most frequent in women
from northern Brazil. It thus constitutes a serious public
health problem in this region [4].
Prophylactic HPV vaccination in Brazil began in March
2014 as part of national immunization program for girls* Correspondence: rodrigobjt@hotmail.com
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creativecommons.org/publicdomain/zero/1.0/aged 9 to 13 years old. The quadrivalent vaccine (Gardasil)
adopted for this program provides protection from the
two hrHPVs found in 70 % of all cases of CC (HPV-16
and HPV-18), as well as protection from two low-risk
HPVs (lrHPV) that cause about 90 % of cases of genital
warts (HPV-6 and HPV-11) [5].
The effects of HPV vaccination on CC rates will only
be apparent after a number of years. A short-term as-
sessment of the impact of the vaccination program can
be provided by the evaluation of the prevalence of type-
specific HPV in vaccinated young women [6, 7], al-
though the systematic evaluation of any change in the
distribution of the virus will depend on the availability of
data from the pre-immunization period, which are cur-
rently unavailable for the study region.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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all mucosal HPV types, including low-risk and hrHPV
types, in female university students from northern Brazil
prior to the introduction of HPV vaccination.
Methods
Between October 2012 and October 2013, cervical speci-
mens were collected from female students as part of a
routine CC screening program based on the Pap test
and analyzed at the Cytology Laboratory of the Federal
University of Pará (UFPA) in Belém, Brazil. After sample
collection, the endocervical brush was washed into
microtubes containing 0.5 mL of saline that were stored
at −20 °C until the molecular analysis. At the UFPA Mo-
lecular and Cellular Biology Laboratory, the viral DNA
was extracted using the standard phenol-chloroform
protocol and purified by ethanol precipitation [8]. Poly-
merase Chain Reaction (PCR) of the human β-globin
gene was conducted prior to HPV detection to confirm
the suitability of the samples [9].
The HPV PCR was conducted using degenerate MY09/
MY11 primers [10] and the HPV-positive cases were
typed by Restriction Fragment Length Polymorphisms
(RFLP) [11], which permit the identification of the 13
hrHPVs classified by the International Agency for Re-
search on Cancer (IARC) as being at least “probably car-
cinogenic to humans” (HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68), twelve possibly high-risk types
(HPV 26, 30, 34, 53, 66, 67, 69,70, 73, 82, 85 and 97) and
other genotypes classified as lrHPVs, including HPV-6
and HPV-11 [12]. The conventional cytology results were
classified according to the Bethesda's terminology [13].
This study was approved by the Human Research Ethics
Committee of the UFPA Center for Tropical Medicine (n°
167.270/2012), in accordance with all the directives and
norms regulating research involving humans in Resolution
n°. 446/2012 of the Brazilian National Health Council. In-
formed consent was obtained from all participants.
Results
A total of 265 university students were included in the
study (mean age 25 ± 5.7 years; range: from 18 to 55 years).
The mean age of first intercourse was 18 ± 2.9 years, and
the mean age at menarche was 12 ± 1.5 years. Most (75 %)
of the individuals had had two or more sexual partners
during their lifetime, 90 % were single, 99 % did not
smoke, and more than half (59 %) used condoms during
sexual relations. Just under half (49 %) of the participants
were having Pap screening for the first time.
No evidence was found of invasive carcinoma in any
of the samples.
High-grade Squamous Intraepithelial Lesions (HSIL)
were found in six samples (2.3 %), and Low-grade le-
sions (LSIL) in 17 (6.4 %), Atypical Squamous Cells ofUndetermined Significance (ASCUS) in 14 (5.3 %), and
Atypical Squamous Cells, cannot exclude HSIL (ASCH)
in one (0.4 %). The other 227 samples analyzed in this
study presented normal cytology (85.7 %).
The DNA of HPV was detected in cervical specimens of
67 women, with an overall prevalence of 25.3 % (67/265).
The prevalence of HPV among women with normal cy-
tology was 23.4 % (53/227), increasing to 36.9 % (14/38) in
women with abnormal cytology of any kind. There was no
statistical association between the occurrence of HPV in-
fections and abnormal cytology (p > 0.05).
Twenty HPV types were detected (Fig. 1), including
seven hrHPVs (16, 18, 45, 52, 58, 59 and 68), five pos-
sibly hrHPVs (26, 53, 66, 70 and 82), and eight lrHPVs
(6, 54, 61, 74, 81, 83, 90 and 106), with no genotype being
determined in six samples. The most frequent genotype
was HPV-61, followed by HPV-82, HPV-16, HPV-59 and
HPV-6. Of the high-risk infections, HPV-16 and HPV-59
were the most prevalent genotypes, which were each de-
tected in seven samples (2.7 %), whereas HPV-61 was the
low-risk genotype most often detected (5.3 %). While
HPV-6 was identified in six samples (2.3 %), HPV-11 was
not detected at all in the present study. The possibly
hrHPVs were observed in 11 samples, of which HPV-82
was the most prevalent genotype (3 %).
Single infections were detected in 59 % (36/61) of the
genotyped samples, while multiple genotypes were identi-
fied in 41 % (25/61). The five most common genotypes in
multiple infections were HPV-82, HPV-16, HPV-18, HPV-
68 and HPV-6. High-risk HPVs and possibly hrHPVs were
found more frequently in multiple infections than in sin-
gle infections. Low-risk genotypes were associated with
single infections (Table 1).
High-risk HPV infections were identified in 26 sam-
ples (9.8 %), of which 12 presented vaccine HPV-16 or
HPV-18 (4.5 %). Overall, non-vaccine hrHPVs were found
in approximately 77 % of the high-risk cases (20/26). Four-
teen individuals were infected exclusively by non-vaccine
hrHPVs and six were co-infected with HPV-16 or HPV-
18. Infections associated exclusively with vaccine hrHPVs
were recorded in only six cases.
Discussion
Our study demonstrated a HPV prevalence of 25.3 %
among unimmunized university students from northern
Brazil. In the Pap test, 85.7 % of the students screened
had normal cytology. Despite the high prevalence of
HPV infection, a low prevalence of vaccine hrHPVs was
detected (4.5 %), with non-vaccine types predominating
in high-risk cases. In addition, some HPVs that present
vaccine cross-protection in vaccine trials due to their
genetic similarities with HPV-16 and HPV-18, mainly
HPV-31, 33, 45, 52 and 58 [14, 15], were also rare in our
study, as were the vaccine lrHPVs (HPV-6 and HPV-11).
Fig. 1 Absolute frequency of the 20 types of HPV detected in single and multiple infections (HPV: human papillomavirus; *oncogenic types)
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was much higher than that found by Bruni et al. [16] in
a meta-analysis of the worldwide data, in which the
overall HPV prevalence among women with normal cy-
tology was 11.7 %. In Brazil, there is considerable vari-
ation in the prevalence of HPVs and the distribution of
genotypes. The prevalence recorded here was much
higher than that found in previous studies in southern
(6.7 %) [17] and southeastern Brazil (11 %) [18], but
lower than that described in a previous study in north-
ern Brazil (29.4 %) [19]. However, all these previous
studies recorded HPV-16 as the most prevalent geno-
type, whereas in the present study, HPV-61 and HPV-82
were the most common, although HPV-16 was the most
frequent hrHPV genotype, together with HPV-59.
The effectiveness of HPV vaccines for the reduction of
the incidence of CC will depend on a number of factors,
including vaccine coverage, the efficacy achieved with
one, two or three doses of the vaccine, the degree of
cross-protection provided against HPV types not included
in the vaccines, and the prevalence of the genotypes forTable 1 Distribution of HPV types according to the mode of infectio
Type of HPV Number of samples Single infection (%)
hrHPV 26 9 (34.6)
possibly hrHPV 11 3 (27.3)
lrHPV 33 24 (72.7)
*Values of less than 0.05 were considered significant
a2 or 3 different genotypes
bCI = Confidence Intervalwhich the vaccines do provide protection [15]. Our study
demonstrated a high prevalence of hrHPVs that are not
prevented by vaccination. Despite the good vaccination
coverage achieved during the first vaccination campaign,
coverage for the second dose fell to 42.2 % in Brazil as a
whole, and only 18.1 % in Pará, where our study was con-
ducted [20].
Multiple infections were very common in our study,
and typically involved hrHPVs and possibly hrHPV ge-
notypes. An association may exist between some pairs of
high-risk genotypes, which may determine their role in
multiple infections [21]. A better understanding of the
mechanisms of synergism or antagonism involved in
high-risk infections will be important for the prediction
of the impact of vaccination programs on the distribu-
tion and replacement of HPV genotypes [22]. The high
frequency of infections by possibly hrHPVs, especially
HPV-82 (the second most prevalent in our study), also
emphasizes the need for stricter epidemiological surveil-
lance of these types in northern Brazil, in addition to
those already classified as hrHPVs.n (single or multiple)
Multiple Infectiona (%) p* Odds Ratio (95 % CI)b
17 (65.4) 0.0021 6.38 (2.06-19.72)
8 (72.7) 0.0428 5.18 (1.21-22)
9 (27.3) 0.0355 0.28 (0.1-0.82)
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procedure adopted in our study represent two potential
limitations, although these considerations are outweighed
by the need for data on the prevalence and distribution of
HPV genotypes from this poorly-studied region, which are
essential for epidemiological monitoring and in particular,
the short-term evaluation of the effectiveness of the vac-
cination program established recently in Brazil. The inclu-
sion of subjects with abnormal cytology may also have
been a limiting factor. Nevertheless, the future evaluation
of the vaccine effectiveness requires pre-vaccination data
both in women with normal and abnormal cytology re-
sults. Moreover, our study sample was not obtained from
a referral centre or colposcopy clinic and only a small pro-
portion of the participants had abnormal cytology, which
did not consistently affect the overall HPV prevalence.
Conclusions
Despite the high prevalence of HPV (25.3 %) in the
study group from northern Brazil, the vaccine hrHPVs
were relatively rare. In other words, there was a predom-
inance of carcinogenic genotypes against which the vac-
cine does not confer immunity. This highlights the need
to reinforce cytological screening as a basic tool for the
early diagnosis and treatment of precancerous CC
lesions in northern Brazil, where CC incidence and
mortality rates are unusually high.
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